Hans Edgar Bishop's Net Worth

$273 Million

Estimate Recalculated Jan 8, 2026 09:07PM EST

Who is Hans Edgar Bishop

Hans Edgar Bishop has an estimated net worth of $273 Million. This is based on reported shares across multiple companies, which include AGILENT TECHNOLOGIES, INC., Sana Biotechnology, Inc., Lyell Immunopharma, Inc., Juno Therapeutics, Inc., CELGENE CORP /DE/, AVANIR PHARMACEUTICALS, INC., and DENDREON CORP.

SEC CIK

Hans Edgar Bishop's CIK is 0001480212

Past Insider Trading and Trends

2016 was Hans Edgar Bishop's most active year for acquiring shares with 11 total transactions. Hans Edgar Bishop's most active month to acquire stocks was the month of May. 2016 was Hans Edgar Bishop's most active year for disposing of shares, totalling 26 transactions. Hans Edgar Bishop's most active month to dispose stocks was the month of May. 2010 saw Hans Edgar Bishop paying a total of $1,999,992.88 for 190,533 shares, this is the most they've acquired in one year. In 2018 Hans Edgar Bishop cashed out on 4,082,434 shares for a total of $214,061,666.43, their largest year based on trade value.

Loading...

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

AGILENT TECHNOLOGIES, INC.

Investor
Updated Mar 19, 2024
Form 4
10.77%
2.43K
$147.48
$358.08K
Mar 19, 2024
24.98K
Grant
Mar 15
Form 4
12.01%
2.40K
$136.82
$328.23K
Mar 20, 2023
22.38K
Grant
Mar 16
Form 4
14.95%
2.58K
$136.82
$353.27K
Mar 21, 2022
19.85K
Grant
Mar 17
Form 4
18.42%
2.67K
$121.59
$324.90K
Mar 22, 2021
17.18K
Grant
Mar 18
Form 4
1.24%
177.00
$93.91
$16.62K
Aug 05, 2020
14.46K
Grant
Aug 03
Form 4
40.59%
4.11K
$73.01
$299.92K
Apr 21, 2020
14.23K
Grant
Apr 17
Form 4
52.42%
3.45K
$82.00
$282.94K
Mar 22, 2019
10.03K
Grant
Mar 21
Form 4
195.41%
4.31K
$67.47
$291.07K
Mar 23, 2018
6.52K
Grant
Mar 22
Form 4
2.20K
$61.21
$134.60K
Jul 18, 2017
2.20K
Grant
Jul 18
Form 3
Jul 18, 2017
Showing 10 results

Sana Biotechnology, Inc.

Investor
Updated Jul 15, 2024
Form 4/A
65.00K
Jul 15, 2024
65.00K
Grant
Jun 06
Form 4
0.08%
4.91K
Jul 08, 2024
5.78M
Grant
Jul 05
Form 4
54.28K
Jun 07, 2024
54.28K
Grant
Jun 06
Form 4
0.05%
2.77K
Apr 08, 2024
5.78M
Grant
Apr 05
Form 4
0.08%
4.90K
Jan 08, 2024
5.78M
Grant
Jan 05
Form 4
0.12%
6.92K
Oct 06, 2023
5.77M
Grant
Oct 05
Form 4
0.07%
4.15K
Jul 06, 2023
5.77M
Grant
Jul 05
Form 4
65.00K
Jun 09, 2023
65.00K
Grant
Jun 08
Form 4
0.13%
7.72K
Apr 06, 2023
5.76M
Grant
Apr 05
Form 4
0.12%
6.70K
Jan 06, 2023
5.75M
Grant
Jan 05
Form 4
0.07%
4.01K
Oct 06, 2022
5.75M
Grant
Oct 05
Form 4
0.06%
3.33K
Jul 07, 2022
5.74M
Grant
Jul 05
Form 4
65.00K
Jun 08, 2022
65.00K
Grant
Jun 06
Form 4
0.05%
2.88K
Apr 06, 2022
5.74M
Grant
Apr 05
Form 4/A
23.59K
Feb 18, 2021
23.59K
Grant
Feb 03
Form 4
Feb 10, 2021
5.74M
Options
Feb 08
Form 4
14.00K
Feb 05, 2021
14.00K
Grant
Feb 03
Form 3
Feb 03, 2021
3.71M
Showing 18 results

Lyell Immunopharma, Inc.

Investor
Updated Jun 17, 2024
Form 4
130.00K
Jun 17, 2024
4.82M
Grant
Jun 14
Form 4
55.00K
Sep 08, 2023
4.74M
Grant
Sep 08
Form 4
65.00K
Jun 20, 2023
4.75M
Grant
Jun 16
Form 4
$0.10
$14.54K
Sep 09, 2022
4.71M
Options
Sep 08
Form 4
65.00K
Jun 10, 2022
4.61M
Grant
Jun 08
Form 4
$0.10
$99.34K
Feb 25, 2022
4.71M
Options
Feb 23
Form 4
Jun 23, 2021
3.55M
Options
Jun 21
Form 3
Jun 16, 2021
3.00M
Showing 8 results

Juno Therapeutics, Inc.

CEO & President
Updated Mar 07, 2018
Form 4
-100.00%
-3.45M
$87.00
Mar 07, 2018
Disposition
Mar 05
Form 4
-4.70%
-120.63K
$85.49
-$371.54K
Feb 09, 2018
2.45M
Grant
Feb 07
Form 4
2.65%
66.43K
Feb 02, 2018
2.57M
Grant
Jan 31
Form 4
-8.38%
-270.25K
$26.27
-$10.92M
Jan 18, 2018
2.95M
Sale
ScheduledJan 16
Form 4
1.44%
35.89K
Oct 20, 2017
2.53M
Grant
Oct 20
Form 4
10.22%
250.00K
Feb 09, 2017
2.70M
Grant
Feb 07
Form 4
-1.38%
-44.00K
$19.68
-$1.17M
Sep 29, 2016
3.14M
Sale
ScheduledSep 27
Form 4
-2.57%
-84.03K
$18.32
-$2.46M
Sep 21, 2016
3.19M
Sale
ScheduledSep 19 - Sep 21
Form 4
-0.70%
-23.04K
$18.21
-$546.03K
Sep 09, 2016
3.27M
Sale
ScheduledSep 08
Form 4
-1.28%
-42.67K
$18.21
-$1.17M
Sep 02, 2016
3.30M
Sale
ScheduledAug 31
Form 4/A
-3.34%
-115.25K
$22.41
-$4.15M
Sep 02, 2016
3.34M
Sale
ScheduledJun 30
Form 4
-3.34%
-115.25K
$22.41
-$4.15M
Jul 01, 2016
3.34M
Options
ScheduledJun 30
Form 4
-2.56%
-90.75K
$26.39
-$3.87M
Jun 13, 2016
3.45M
Sale
ScheduledJun 09
Form 4
-2.50%
-90.75K
$20.84
-$2.86M
Mar 02, 2016
3.54M
Sale
ScheduledFeb 29
Form 4
200.00K
Feb 04, 2016
200.00K
Grant
Feb 02
Form 4
-2.46%
-91.50K
$26.04
-$3.84M
Dec 17, 2015
3.63M
Sale
ScheduledDec 15
Form 4
140.00K
Mar 05, 2015
140.00K
Grant
Mar 03
Form 3
Dec 18, 2014
2.72M
Showing 18 results

CELGENE CORP /DE/

Investor
Updated Nov 22, 2019
Form 4
-100.00%
-52.56K
Nov 22, 2019
Disposition
Nov 20
Form 4
4.76K
Jun 05, 2019
4.76K
Grant
Jun 03
Form 4
14.72K
Jun 15, 2018
14.72K
Grant
Jun 13
Form 3
Apr 19, 2018
23.09K
Showing 4 results

AVANIR PHARMACEUTICALS, INC.

Investor
Updated Feb 14, 2014
Form 4
44.84%
28.90K
Feb 14, 2014
93.35K
Grant
Feb 12
Form 4
43.22%
19.45K
Feb 19, 2013
64.45K
Grant
Feb 14
Form 4
45.00K
May 25, 2012
45.00K
Grant
May 23
Form 3
May 15, 2012
Showing 4 results

DENDREON CORP

Chief Operating Officer
Updated Aug 02, 2011
Form 4
-1.49%
-2.29K
$37.65
-$86.26K
Aug 02, 2011
151.19K
Tax
Jul 29
Form 4
-1.50%
-2.34K
$42.27
-$99.00K
May 03, 2011
153.48K
Tax
Apr 29
Form 4
-5.59%
-9.23K
$35.01
-$323.11K
Feb 11, 2011
155.82K
Tax
Feb 10
Form 4
20.48%
28.05K
Jan 24, 2011
165.05K
Grant
Jan 20
Form 4
73.21%
80.53K
$37.36
$2.00M
Dec 09, 2010
190.53K
Grant
Dec 07
Form 4
110.00K
Feb 01, 2010
110.00K
Grant
Jan 29
Form 3
Jan 11, 2010
Showing 7 results